Huntsman Q2 Beat and Olin Merger Signal a Potential Turnaround

What happened

Huntsman reported a narrower-than-expected Q2 loss and a revenue beat, driven by higher volumes and pricing across all segments, indicating early signs of a cyclical recovery. The company also disclosed that its planned merger with Olin is advancing toward a stockholder vote, adding a potential transformative catalyst. Despite these positive developments, Huntsman remains in a net loss position, with elevated leverage (net debt/EBITDA ~5.8x) and negative interest coverage, as highlighted in the latest DeepValue report. While the Q2 results suggest the trough may be passing, merger integration risk and uncertain synergy realization temper the outlook. Overall, the news offers a near-term positive signal, but deep value concerns persist.

Implication

Investors should view the Q2 beat as a tentative sign that Huntsman's cyclical trough may be ending, supported by higher volumes and pricing. The Olin merger, if approved, could create a more diversified chemical platform with potential cost synergies, but integration risks are material. Despite the positive news, Huntsman's balance sheet remains stretched, and the stock still trades above a conservative DCF estimate, limiting margin of safety. The merger may distract from ongoing restructuring efforts and could face regulatory hurdles. A more constructive stance is warranted only if the merger demonstrates clear value creation and earnings recovery is sustained over multiple quarters.

Thesis delta

The thesis shifts from a cautious WAIT to a guarded WATCH with upside potential, contingent on successful Olin merger integration and sustained operational improvement. Key risks remain high leverage and merger execution uncertainty.